Stockreport

Axovant Has Promise, But Downside Risk Still Outweighs Prospects [Seeking Alpha]

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF Summary Axovant recently failed in Phase II for flagship candidate nelotenserin and decided to discontinue the program. There is still ample promise in [Read more]